Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.35 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.35 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2693461 | 0.79 | TSHR (0.41) | KMT2AMEN1TSHRHPGDALDH1A1 | |
| SCHEMBL2130266 | 0.79 | KMT2A (0.34) | KMT2AMEN1TSHRHPGDPOLB | |
| SCHEMBL4213544 | 0.76 | FGFR1 (0.39) | TSHRKDM4EFGFR1FGFR2FGFR4 | |
| SCHEMBL4074571 | 0.73 | MEN1 (0.43) | KMT2AMEN1TSHRALDH1A1LMNA | |
| SCHEMBL4578218 | 0.73 | FGFR1 (0.36) | TSHRALDH1A1KDM4EFGFR1FGFR2 | |
| SCHEMBL13358949 | 0.72 | FGFR1 (0.37) | TSHRALDH1A1KDM4EMAPK1FGFR1 | |
| SCHEMBL4068215 | 0.72 | FGFR1 (0.35) | KMT2AMEN1TSHRPOLBNPC1 | |
| SCHEMBL2126522 | 0.71 | KCNA5 (0.37) | KMT2AMEN1POLBKCNA5FGFR1 | |
| SCHEMBL2127136 | 0.70 | FGFR1 (0.37) | TSHRMAPK1FGFR1FGFR2FGFR4 | |
| SCHEMBL4215152 | 0.70 | SORD (0.42) | TSHRALDH1A1KDM4EMAPK1FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318931-B2 | Chemokine receptor antagonists and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-11-27 | — | — | US | disclosed |
| US-8293896-B2 | — | — | 2012-10-23 | — | — | US | disclosed |
| US-20090118279-A1 | COMPOUND CONTAINING BASIC GROUP AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD., (JP) | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118279-A1 | COMPOUND CONTAINING BASIC GROUP AND USE THEREOF | CXCR4, CXCR1, CXCR3 | KMT2A 3385/4885MEN1 2513/4885TSHR 2323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.